Loading...
Market
Will Pfizer announce another Phase 3 trial for Sasanlimab by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Pfizer official announcements and press releases
Story
Pfizer's Phase 3 Study Shows Sasanlimab with BCG Improves Event-Free Survival in High-Risk Non-Muscle Invasive Bladder Cancer
Jan 10, 2025, 11:52 AM
Pfizer has announced positive topline results from its Phase 3 study indicating that Sasanlimab, when combined with Bacillus Calmette-Guérin (BCG), improves event-free survival in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The study met its primary endpoint as assessed by investigators. Pfizer also reported that the safety profile of Sasanlimab was consistent with previous findings, suggesting a favorable outcome for this treatment approach in a challenging patient population.
View original story
Similar markets
Negative efficacy, but good safety • 25%
Positive efficacy and safety results • 25%
Negative efficacy and safety concerns • 25%
Positive efficacy, but safety concerns • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%